Overview

Dose Response to Recombinant Factor VIIa When Administered for Bleed

Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
0
Participant gender:
Male
Summary
This trial is conducted in the United States of America (USA). The purpose of this trial is to investigate the dose response to recombinant factor VIIa in healthy volunteers when administered for bleed.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Novo Nordisk A/S
Criteria
Inclusion Criteria:

- Ages Eligible for Study: 18 Years - 60 Years

Exclusion Criteria:

- - -